Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells

Molecular Nutrition and Food Research

Volumn 59, Issue 2, 2015, Pages 250-261

  Wang, Piwen ^a,b   Phan, Tien ^a   Gordon, David ^a   Chung, Seyung ^a   Henning, Susanne M ^b   Vadgama, Jaydutt V ^a,c  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arctigenin; Combination; MicroRNA; Prostate cancer; Quercetin

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; ARCTIGENIN; FURAN DERIVATIVE; LIGNAN; MICRORNA; MIRN148 MICRORNA, HUMAN; MIRN19 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROGENS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FURANS; HUMANS; LIGNANS; MALE; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84922760249     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400558     Document Type: Article

References (49)

1. American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society, Atlanta, GA 2014.
2. Griffiths, K., Prezioso, D., Turkes, A., Denis, L. J., The prevention of prostate cancer. Recent Results Cancer Res. 2007, 175, 33-63.
3. Neal, D. E., Donovan, J. L., Prostate cancer: to screen or not to screen? Lancet Oncol. 2000, 1, 17-24.
4. Delpierre, C., Lamy, S., Kelly-Irving, M., Molinie, F. et al., Life expectancy estimates as a key factor in over-treatment: the case of prostate cancer. Cancer Epidemiol. 2013, 37, 462-468.
5. Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A. et al., Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100, 892-899.
6. Adhami, V. M., Siddiqui, I. A., Ahmad, N., Gupta, S. et al., Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004, 64, 8715-8722.
7. Henning, S. M., Wang, P., Heber, D., Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol. Nutr. Food Res. 2011, 55, 905-920.
8. Cimino, S., Sortino, G., Favilla, V., Castelli, T. et al., Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid. Med. Cell Longev. 2012, 2012, 632959.
9. Yang, C. S., Wang, X., Green tea and cancer prevention. Nutr. Cancer 2010, 62, 931-937.
10. Hamalainen, M., Nieminen, R., Vuorela, P., Heinonen, M. et al., Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007, 2007, 45673.
11. Morgan, T. M., Koreckij, T. D., Corey, E., Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets 2009, 9, 237-249.
12. Graefe, E. U., Wittig, J., Mueller, S., Riethling, A. K. et al., Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 2001, 41, 492-499.
13. Day, A. J., Mellon, F., Barron, D., Sarrazin, G. et al., Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic. Res. 2001, 35, 941-952.
14. Zhao, F., Wang, L., Liu, K., In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J. Ethnopharmacol. 2009, 122, 457-462.
15. He, F., Dou, D. Q., Sun, Y., Zhu, L. et al., Plasma pharmacokinetics and tissue distribution of arctiin and its main metabolite in rats by HPLC-UV and LC-MS. Planta Med. 2012, 78, 800-806.
16. Hyam, S. R., Lee, I. A., Gu, W., Kim, K. A. et al., Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages. Eur. J. Pharmacol. 2013, 708, 21-29.
17. Awale, S., Lu, J., Kalauni, S. K., Kurashima, Y. et al., Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006, 66, 1751-1757.
18. Matsuzaki, Y., Koyama, M., Hitomi, T., Yokota, T. et al., Arctiin induces cell growth inhibition through the down-regulation of cyclin D1 expression. Oncol. Rep. 2008, 19, 721-727.
19. Huang, D. M., Guh, J. H., Chueh, S. C., Teng, C. M., Modulation of anti-adhesion molecule MUC-1 is associated with arctiin-induced growth inhibition in PC-3 cells. Prostate 2004, 59, 260-267.
20. Yang, G. Y., Liao, J., Li, C., Chung, J. et al., Effect of black and green tea polyphenols on c-jun phosphorylation and H(2)O(2) production in transformed and non-transformed human bronchial cell lines: possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis 2000, 21, 2035-2039.
21. Chou, T. C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70, 440-446.
22. Wang, P., Aronson, W. J., Huang, M., Zhang, Y. et al., Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev. Res. 2010, 3, 985-993.
23. Henning, S. M., Wang, P., Said, J., Magyar, C. et al., Polyphenols in brewed green tea inhibit prostate tumor xenograft growth by localizing to the tumor and decreasing oxidative stress and angiogenesis. J. Nutr. Biochem. 2012, 23, 1537-1542.
24. Milenkovic, D., Jude, B., Morand, C., miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med. 2013, 64, 40-51.
25. Boesch-Saadatmandi, C., Wagner, A. E., Wolffram, S., Rimbach, G., Effect of quercetin on inflammatory gene expression in mice liver in vivo-role of redox factor 1, miRNA-122 and miRNA-125b. Pharmacol. Res. 2012, 65, 523-530.
26. Milenkovic, D., Deval, C., Gouranton, E., Landrier, J. F. et al., Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: a new mechanism of the action of polyphenols. PLoS One 2012, 7, e29837.
27. Lochter, A., Srebrow, A., Sympson, C. J., Terracio, N. et al., Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J. Biol. Chem. 1997, 272, 5007-5015.
28. Yang, C. S., Sang, S., Lambert, J. D., Lee, M. J., Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol. Nutr. Food Res. 2008, 52(Suppl 1), S139-151.
29. Manach, C., Williamson, G., Morand, C., Scalbert, A. et al., Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S-242S.
30. Egert, S., Wolffram, S., Bosy-Westphal, A., Boesch-Saadatmandi, C. et al., Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J. Nutr. 2008, 138, 1615-1621.
31. Conquer, J. A., Maiani, G., Azzini, E., Raguzzini, A. et al., Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 1998, 128, 593-597.
32. Wang, P., Heber, D., Henning, S. M., Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr. Cancer 2012, 64, 580-587.
33. Wang, P., Vadgama, J. V., Said, J. W., Magyar, C. E. et al., Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J. Nutr. Biochem. 2014, 25, 73-80.
34. Armbruster, D. A., Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin. Chem. 1993, 39, 181-195.
35. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M. et al., Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999, 13, 966-977.
36. Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H. et al., Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19, 575-586.
37. Luo, J., Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009, 273, 194-200.
38. Klampfer, L., Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 2006, 6, 107-121.
39. Park, H. U., Suy, S., Danner, M., Dailey, V. et al., AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol. Cancer Ther. 2009, 8, 733-741.
40. Meshki, J., Caino, M. C., von Burstin, V. A., Griner, E. et al., Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway. J. Biol. Chem. 2010, 285, 26033-26040.
41. Lu, Y. Z., Deng, A. M., Li, L. H., Liu, G. Y. et al., Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer. Arch. Med. Sci. 2014, 10, 149-153.
42. Ma, Q., Guin, S., Padhye, S. S., Zhou, Y. Q. et al., Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol. Cancer 2011, 10, 66.
43. Hasima, N., Aggarwal, B. B., Cancer-linked targets modulated by curcumin. Int. J. Biochem. Mol. Biol. 2012, 3, 328-351.
44. Milenkovic, D., Jude, B., Morand, C., miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med. 2013, 64, 40-51.
45. Lam, T. K., Shao, S., Zhao, Y., Marincola, F. et al., Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues. Cancer Epidemiol. Biomarkers Prev. 2012, 21, 2176-2184.
46. Ribas, J., Ni, X., Haffner, M., Wentzel, E. A. et al., miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69, 7165-7169.
47. Fang, Y. X., Gao, W. Q., Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2014, 33, 135-147.
48. Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L. et al., STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39, 493-506.
49. Olive, V., Bennett, M. J., Walker, J. C., Ma, C. et al., miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009, 23, 2839-2849.